We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+16.66%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.04B
AUM Growth
+$465M
Cap. Flow
+$311M
Cap. Flow %
15.21%
Top 10 Hldgs %
65.12%
Holding
37
New
14
Increased
6
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$108M
2
UHS icon
Universal Health Services
UHS
+$83.4M
3
GSK icon
GSK
GSK
+$55.4M
4
MDCO
Medicines Co
MDCO
+$49.3M
5
TSRO
TESARO, Inc.
TSRO
+$44.1M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$82.5M
2
NKTR icon
Nektar Therapeutics
NKTR
+$72.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$58.3M
4
OFIX icon
Orthofix Medical
OFIX
+$45.4M
5
GILD icon
Gilead Sciences
GILD
+$40.5M

Sector Composition

Rank Sector Weight
1 Healthcare 61.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$400M 19.59%
1,500,000
– –
NKTR icon
2
Nektar Therapeutics
NKTR
$2.41B
$200M 9.79%
223,333
-123,334
-36% -$72.9M
HCA icon
3
HCA Healthcare
HCA
$85.7B
$110M 5.37%
1,250,000
+450,000
+56% +$36.2M
VTRS icon
4
Viatris
VTRS
$20.7B
$106M 5.18%
2,500,000
-200,000
-7% -$7.65M
AGN
5
DELISTED
Allergan plc
AGN
$98.1M 4.8%
+600,000
New +$108M
UHS icon
6
Universal Health Services
UHS
$9.88B
$88.4M 4.33%
+780,000
New +$83.4M
THC icon
7
Tenet Healthcare
THC
$21.8B
$87.2M 4.27%
5,750,000
– –
EVHC
8
DELISTED
Envision Healthcare Holdings Inc
EVHC
$86.4M 4.23%
2,500,000
+1,000,000
+67% +$35M
GHDX
9
DELISTED
Genomic Health, Inc.
GHDX
$84.1M 4.11%
2,458,100
– –
TSRO
10
DELISTED
TESARO, Inc.
TSRO
$70.4M 3.45%
850,000
+450,000
+113% +$44.1M
BKD icon
11
Brookdale Senior Living
BKD
$3.49B
$63M 3.09%
6,500,000
+1,100,000
+20% +$11.2M
BIVV
12
DELISTED
Bioverativ Inc. Common Stock
BIVV
$59.1M 2.89%
1,096,000
+96,000
+10% +$5.25M
TEVA icon
13
CALL
Teva Pharmaceuticals
TEVA
$41.2B
$56.9M 2.78%
+3,000,000
New +$45.1M
GSK icon
14
GSK
GSK
$104B
$53.2M 2.6%
+1,200,000
New +$55.4M
EXAS
15
PUT
DELISTED
Exact Sciences
EXAS
$52.5M 2.57%
+1,000,000
New +$53.4M
MYGN icon
16
Myriad Genetics
MYGN
$507M
$51.5M 2.52%
1,500,000
-500,000
-25% -$16.9M
MDCO
17
DELISTED
Medicines Co
MDCO
$43.7M 2.14%
+1,600,000
New +$49.3M
ELGX
18
DELISTED
Endologix Inc
ELGX
$42.8M 2.09%
800,000
– –
CLVS
19
DELISTED
Clovis Oncology, Inc.
CLVS
$40.8M 2%
600,000
+400,000
+200% +$28M
AMAG
20
DELISTED
AMAG Pharmaceuticals
AMAG
$35.1M 1.72%
2,650,000
– –
RDUS
21
DELISTED
Radius Health, Inc.
RDUS
$31.8M 1.56%
1,000,000
-150,000
-13% -$4.71M
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
$31.5M 1.54%
+800,000
New +$29.9M
OFIX icon
23
Orthofix Medical
OFIX
$477M
$27.4M 1.34%
500,000
-875,000
-64% -$45.4M
ALKS icon
24
Alkermes
ALKS
$8.39B
$21.9M 1.07%
+400,000
New +$20.4M
NVTA
25
DELISTED
Invitae Corporation
NVTA
$21.8M 1.07%
2,398,123
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Camber Capital Management held 37 positions worth $2.04B, up 29% from $1.58B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Camber Capital Management deployed $311M of net new capital in Q4 2017, opening 14 new positions and adding to 6 existing holdings. Its largest new stake was Allergan plc: 600,000 shares worth $98.1M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 62% a quarter earlier.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $72.9M trimmed.

  • Camber Capital Management's largest Q4 2017 buy was Allergan plc: 600,000 shares worth $98.1M.
  • Camber Capital Management added most to TESARO, Inc. in Q4 2017, an estimated $44.1M increase.
  • Camber Capital Management's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $72.9M.
  • Camber Capital Management fully exited Perrigo in Q4 2017, selling an estimated $82.5M.
  • Camber Capital Management's ten largest holdings make up 65% of its $2.04B portfolio in Q4 2017.
  • Camber Capital Management opened 14 new positions and closed 3 in Q4 2017.
  • Camber Capital Management's portfolio value rose 29% quarter-over-quarter to $2.04B.

Based on Camber Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.